1Sung P,Krejci L,Van Komen S,et al.Rad51 recombinase and recombination mediators[J].J Biol Chem,2003,278(44):42729-32.
2Welsh JW,Ellsworth RK,Kumar R,et al.Rad51 protein expression and survival in patients with glioblastoma multiforme[J].Int J Radiat Oncol Biol Phys,2009,74(4):1251-5.
3Klein HL.The consequences of Rad51 overexpression for normal and tumor cells[J].DNA Repair (Amst),2008,7(5):686-93.
4Henning W,Stürzbecher HW.Homologous recombination and cell cycle checkpoints:Rad51 in tumour progression and therapy resistance[J].Toxicology,2003,193(1-2):91-109.
5Blasiak J,Przybyl K,Czechowska A,et al.Analysis of the G/C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer[J].Acta Biochim Pol,2003,50(1):249-53.
6Slupianek A,Schmutte C,Tombline G,et al.BCR/ABL regulates mammalian RecA homologs,resulting in drug resistance[J].Mol Cell,2001,8(4):795-806.
7Slupianek A,Hoser G,Majsterek I,et al.Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair,prolongation of G(2)/M phase,and protection from apoptosis[J].Mol Cell Biol,2002,22(12):4189-201.
8Bishop DK,Ear U,Bhattacharyya A,et al.Xrcc3 is required for assembly of Rad51 complexes in vivo[J].J Biol Chem,1998,273(34):21482-8.
9Jeggo PA.DNA-PK:at the cross-roads of biochemistry and genetics[J].Mutat Res,1997,384(1):1-14.
10Chou A J, Gorlick R. Chemotherapy resistance in osteosarcoma:current challenges and future directions[J]. Exp Rev Anti Ther,2006,6(7) : 1075 - 1085.
